PATENT CLAIM ANALYSIS

Application Number: 15924020
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "210210"]

Abstract:
A series of fused bicyclic heteroaromatic derivatives of formula (IA) or (IB), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.

Claim (Index 18):
A method for the treatment and/or prevention of an inflammatory, autoimmune or oncological disorder, a viral disease or malaria, or organ or cell transplant rejection, which comprises administering to a patient in need of such treatment an effective amount of a compound of formula (IA) or (IB) as defined in  claim 1  or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 90.0
- Lexical Diversity: 1.30612
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15318422', '15318507', '14357340', '14432842', '15513357']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7944329345248319
- 35 USC 102 Novelty (BERT): 0.5629818148903752
- Combined Prediction Score: 0.7712878225613863
- Mean Citation Score: 396.094192
- Max Citation Score: 420.13782
- Similarity Product: 385.37348447888377

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test